Sareum Holdings plc (AIM:SAR)

Market Cap	19.49M
Revenue (ttm)	n/a
Net Income (ttm)	-2.83M
Shares Out	134.41M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,436
Average Volume	303,694
Open	14.90
Previous Close	14.50
Day's Range	14.35 - 16.10
52-Week Range	11.00 - 52.50
Beta	-1.69
RSI	41.66
Earnings Date	Jun 23, 2025

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR